ADIA Nutrition is an early-stage regenerative medicine company focused on stem cell therapies and biologic products. ADIA operates through two activities: running its own medical clinic in Florida (Adia Med of Winter Park) where it administers stem cell treatments to patients, and selling biologic products to third-party healthcare providers. Its two core products are AdiaVita, a private-label umbilical cord blood plasma product used for orthopedic issues, pain management, wound repair, and anti-aging, and AdiaLink, an exosome product derived from amniotic fluid marketed for clinical and research use. ADIA sources raw materials from FDA-approved cord blood banks and processes them under cGMP lab conditions. Revenue comes from patient fees at its own clinics and product sales to third-party regenerative medicine providers. ADIA's growth plan focuses on expanding its clinic footprint nationally through satellite locations, and broadening its third-party distribution network. Longer term, ADIA aims to offer more complex procedures like Autologous Hematopoietic Stem Cell Transplantation for conditions like Multiple Sclerosis and Therapeutic Plasma Exchange for diseases like Alzheimer's. ADIA is very early-stage — it only began seeing patients and generating revenue in January 2025 and has just three employees. ADIA also holds an 18% stake in Cement Factory, a direct-to-consumer supplement business, which is a minor, non-core investment.